Please use this identifier to cite or link to this item:
Title: Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results from the HIV Prevention Trials Network 052 Trial
Authors: Jessica M. Fogel
Sarah E. Hudelson
San San Ou
Stephen Hart
Carole Wallis
Mariza G. Morgado
Shanmugam Saravanan
Srikanth Tripathy
Laura Hovind
Estelle Piwowar-Manning
Devin Sabin
Marybeth McCauley
Theresa Gamble
Xinyi C. Zhang
Joseph J. Eron
Joel E. Gallant
Johnstone Kumwenda
Joseph Makhema
Nagalingeswaran Kumarasamy
Suwat Chariyalertsak
James Hakim
Sharlaa Badal-Faesen
Victor Akelo
Mina C. Hosseinipour
Breno R. Santos
Sheela V. Godbole
Jose H. Pilotto
Beatriz Grinsztejn
Ravindre Panchia
Kenneth H. Mayer
Ying Q. Chen
Myron S. Cohen
Susan H. Eshleman
Keywords: Medicine
Issue Date: 1-Jul-2016
Abstract: © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved. Early initiation of antiretroviral treatment (ART) reduces HIV transmission and has health benefits. HIV drug resistance can limit treatment options and compromise use of ART for HIV prevention. We evaluated drug resistance in 85 participants in the HIV Prevention Trials Network 052 trial who started ART at CD4 counts of 350-550 cells per cubic millimeter and failed ART by May 2011; 8.2% had baseline resistance and 35.3% had resistance at ART failure. High baseline viral load and less education were associated with emergence of resistance at ART failure. Resistance at ART failure was observed in 7 of 8 (87.5%) participants who started ART at lower CD4 cell counts.
ISSN: 10779450
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.